Neurofibromatosis is caused due to a genetic mutation, resulting in the formation of tumors in various parts of a body, along nerve tissues, brain, and spinal cord. Among the three types of this disease, neurofibromatosis type I (NF1) is the most common. Often diagnosed in early adulthood or childhood, NF1 records to affect one behind each 2,000-2,500 people worldwide. Neurofibromatosis type I is characterized by severe skin pigmentation i.e. skin color changes, in addition to tumor formation. These tumors, though benign initially, may turn malignant in later stages; and thus make it critical to seek the appropriate treatment in early stages.
Symptoms of neurofibromatosis type I typically include multiple flat patches or café-au-lait spots, which enlarge and multiply as patients grow older. On the other side, those in late childhood may develop freckles in groin and/or underarms. Although symptoms of the disease are relatively mild, it may progress with complicating consequences, such as extreme pain, loss of vision, loss of hearing, problems related to heart and blood vessels, learning impairment, and ADHD.
As far as treatment for NF1 is concerned, surgery can deal with large-sized tumors that press on nerves along which they are formed. However, a complete range of treatment options, such as medication/drug therapy, targeted therapy, genetic counseling, stereotactic radiosurgery, and palliative care, is available to address differing patient needs.
NF1 occurrence is also accompanied by higher risk of acquiring other types of cancers, leukaemia and brain tumor to name a few. Moreover, there are nearly 50% chances of inheritance in neurofibromatosis type I cases, when one of the parent, siblings, or close relatives is already carrying it. These potential consequences make it necessary to have an effective set of treatments against NF1. The ultimate aim of treatment remains managing complications at the earliest, healthy growth of patients, and maximized survival. Neurofibromatosis type I treatment, management, and therapeutics are witnessing moderate demand globally.
NF1 treatment does not assure complete cure and involves constant medication throughout the therapeutic course, which plays a key role in raising the demand for the disease treatment. Multiple clinical trials required for treating this disease also positively influence the NF1 treatment market growth.
Neurofibromatosis Type I Market: Segmentation
Based on treatment, the neurofibromatosis market is primarily segmented into diagnostics, medication or drug therapy, surgery, focused radiation therapy, chemotherapy, genetic counseling, and palliative care. Surgeries can cure completely remove tumors but always have chances of nerve damage, whereas focused radiation therapy effectively reduces tumor size and minimizes the risk of acquiring paralysis. Drug therapy in combination with chemotherapy does not ascertain 100% effectivity and complete tumor removal. Researchers are taking efforts toward developing new drug lines for complete and effective cure of this disease, which holds positive growth prospects for the market.
Neurofibromatosis Type I Market: Key Players
Key players competing in the neurofibromatosis type I market include various organizations and research institutes. GL Pharm Tech Corporation, Erasmus Medical Center, Assistance Publique – Hopitaux de Paris, Texas Neurofibromatosis Foundation, University of Alabama at Birmingham, and Indiana University are some of the top names in the key players list.
Since the occurrence of neurofibromatosis varies from region to region, the report represents extensive geographical analysis to conclude the level of prominence of NF1 in the seven key regions, including North America, Latin America, Western Europe, Eastern Europe, Asia Pacific, and Middle East and Africa.
The report offers a comprehensive evaluation of the market. It does so via in-depth insights, understanding market evolution by tracking historical developments, and analyzing the present scenario and future projections based on optimistic and likely scenarios. Each research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology developments, types, applications, and the competitive landscape.
The study is a source of reliable data on:
- Key market segments and sub-segments
- Evolving market trends and dynamics
- Changing supply and demand scenarios
- Quantifying market opportunities through market sizing and market forecasting
- Tracking current trends/opportunities/challenges
- Competitive insights
- Opportunity mapping in terms of technological breakthroughs
The regional analysis covers:
- North America (U.S. and Canada)
- Latin America (Mexico, Brazil, Peru, Chile, and others)
- Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, Luxembourg)
- Eastern Europe (Poland, Russia)
- Asia Pacific (China, India, Japan, ASEAN, Australia and New Zealand)
- Middle East and Africa (GCC, Southern Africa, North Africa)
TMR estimates the market size of various sectors using a combination of available data on the number and revenue of companies within each sub-sector and tiers of companies. The basic components used to determine market size and forecast for a specific product area are not only limited to supply-side data, but are also related to demand, industry trends, and the economic outlook. All the above data points are utilized to generate a statistical model targeting the sector marketplace. More than 300 TMR analysts across the world integrate these elements into a framework to determine the subsector market size for a base year and then forecast growth within each market.
TMR regularly interviews technology and business professionals as an ongoing effort to track the latest developments within each sector. These continuous surveys are stratified by company size and industry segment and weighted to reflect the global market place. All data are collected on an ongoing effort through a structured questionnaire rolled over the web or conducted via telephones. This provides the TMR team opportunities to request for detailed question sets, complex skip patterns, and real-time calculations, which assists respondents in answering questions involving numbers and percentages. Respondents, who are interviewed as experts, are screened and qualified based on certain criteria in addition to their decision-making authority and the scope of activity within their organizations.
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.
Note : All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Transparency Market Research.